Parathyroid hormone in the treatment of osteoporosis;La hormona paratiroidea en el tratamiento de la osteoporosis

Anales de Medicina Interna

Volumn 24, Issue 2, 2007, Pages 87-97

  Sosa Henríquez, Manuel ^a,c   Diez Perez A ^b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Anabolic; Bone mineral density; Fracture; Osteoporosis; Postmenopausal; PTH; Risk; Treatment; Women

Indexed keywords

GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; TERIPARATIDA; UNCLASSIFIED DRUG;

BONE DENSITY; BONE REMODELING; CELL ACTIVITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT DURATION; CASE REPORT; CLINICAL TRIAL; FEMALE; MALE;

CLINICAL TRIALS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 34548029359     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. NIH consensus panel. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA. 2001; 285: 785-95.
3. Recker RR, Barger-Lux MJ. The elusive concept of bone quality. Curr Osteoporos Rep 2004; 2: 97-100.
4. Sosa Henríquez M. Consecuencias de la osteoporosis. En: Rapado Errazti A, Díaz Curiel M, Galindo P, editores. Osteoporosis: una guía para profesionales de la Salud. Madrid: Fundación Hispana de Osteoporosis y Enfermedades Metabólicas Óseas (FHOEMO); 1997. p. 21-4.
5. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7.
6. Sosa Henríquez M, Díez Pérez A. Osteoporosis. Concepto. Etiopatogenia. Clínica. Medicine 2006; 9 (Extr. 1): 8-14.
7. Sosa Henríquez M, Hernández Hernández D. Tratamiento de la osteoporosis. Medicine. 2006; 9 (Extr. 1): 35-9
8. Bilezikian JP, Rosen CJ. Clinical Review 123: Hot Topic. Anabolic Therapy for Osteoporosis. J Clin Endocrinol Metab 2001; 86: 957-64.
9. González Macias J, Olmos Martínez J. Fisiopatología de la osteoporosis. Medicine 2006; 9 (Extr. 1): 1-7
10. Eastell R. Pathogenesis of Postmenopausal Osteoporosis. En: Primer on the Metabolic Disease and Disorders of Mineral Metabolism, 6th Edition. Ed MJ Favus. American Society for Bone and Mineral research. Washington; 2006. p. 259-62.
11. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-8.
12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
13. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.
14. Dresner-Pollak R, Parker RA, Poku M, Thompson J Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 1996; 59: 328-33.
15. Garnero P, Sornay-Rendu E, Chapuy MC. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337-49.
16. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS study. J Bone Miner Res 1996; 11: 1531-8.
17. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 2004; 19: 330-7.
18. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80: 723-8.
19. Parisien M, Cosman F, Mellish RWE, Schnitzer M, Nieves J, Silverberg SJ, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Miner Res 1995; 10: 1393-9.
20. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, et al. On the mechanism of cancellous bone preservation in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1999; 84: 1562-6.
21. Morley P, Whitfield JF, Willick GE. Anabolic effects of PTH on bone. Trends Endocrinol Metab 1997; 8: 225-31.
22. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST et al. Parathyroid Hormone and teriparatida for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocrine Rev 2005; 26: 688-703.
23. Reeve J, Tregear GW. Parsons JA. Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis Calcif Tissue Res 1976; 21 (Supl.): 469-77.
24. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976; 1 (7968): 1035-8.
25. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340-4
26. Slovik DM, Rosenthal DI, Doppelt S, Potts JT, Daly MA, Campbell JA, et al. Restoration of spine bone mass in osteoporotic men by treatment with hPTH and 1,25 vitamin D. J Bone Miner Res 1986; 1: 377-81.
27. Frost HM. Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res 1979; (143): 227-44.
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344; 1434-41.
29. Genant HK, Siris E, Crans GG, Desaiah D, Krege JH. Reduction in vertebral fracture risk in teriparatida-treated postmenopausal women as assessed by spinal deformity index. Bone 2005; 37: 170-4.
30. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH. The effects of teriparatida on the incidence of back pain in postmenopausal women with osteoporosis. Curr Medi Res Opinión 2005; 7: 1027-34.
31. Gallagher JC, Genant HK, Crans GG, Vargas Socorro J, Krege JH. Teriparatida reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005; 90: 1583-7.
32. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, et al. Reduced risk of back pain following teriparatida treatment: a meta-analysis. Osteoporos Int 2006; 17: 273-80.
33. Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: Results from the teriparatida randomized, placebo-controlled trial in postmenopausal women. J Rheumatol 2003; 30: 1579-83.
34. Crans GG, Silverman SL, Genant HK, Glass EV,Krege JH. Association of severe vertebral fractures with reduced quality of life reduction in the incidence of severe vertebral fractures by teriparatida. Arthritis Rheumatism 2004; 50: 4028-34.
35. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-5.
36. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatida (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-35
37. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82: 620-8
38. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) (teriparatida) improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18: 1932-41.
39. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16: 1846-53.
40. Burr D. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 2005, 3: 19-24.
41. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Related Articles, Effects of teriparatida (recombinant human parathyroid hormone (1-34)) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 539-43.
42. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26
43. Cosman F, Nieves J, Woelfert L, Formica CA, Gordon SL, Shen V, et al. Parathyroid hormone added to established hormone replacement therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16: 925-931.
44. Compston J. Recombinant Parathyroid Hormone in the Management of Osteoporosis. Calcif Tissue Int 2005; 77: 65-71.
45. Khosla S. Parathyroid hormone plus alendronate: A combination that does not add up. N Engl J Med 2003; 349-1277-9.
46. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ. et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88: 5212-20.
47. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007; 146: 326-39.
48. Greenspan SL, Marriott TB, Hanley DA, Zanchetta JR, Bone HG, Ettinger MP, et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): results from the TOP study (abstract). J Bone Miner Res 2005, 20 (Supl. 1): 556.
49. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al, for the PaTH Study Investigators: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
50. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al, for the PTH and Alendronate (PaTH) Research Group. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006; 91: 1370-5.
51. Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005; 5: 356-7.
52. Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, et al. Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. J Clin Endocrin Metab. First published ahead of print December 12, 2006 as doi: 10.1210/jc.2006-1788
53. Rittmaster RS, Bolognese RS, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate. J Clin Endocrinol Metab 2000; 85: 2129-34.
54. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med 1980; 303: 1377-83.
55. Stewart AF, Vignery A, Silvergate A, Ravin ND, LiVolsi V, Broadus AE, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982; 55: 219-27.
56. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996; 81: 607-11.
57. Strewler GJ The physiology of parathyroid hormone-related protein. N Engl J Med 2000; 342: 177-85.
58. Strewler GJ, Nissenson RA. Hypercalcemia in malignancy. West J Med 1990; 153: 635-40.
59. Wysolmerski, JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. Annu Rev Med 1994; 45: 189-200.
60. Grill V, Rankin W, Martin TJ. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur. J. Cancer. 1998; 34: 222-9.
61. Miao D Bin He B, Jiang Y, Kobayash T, Sorocéanu MA, et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005; 115: 240-11.
62. Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992; 89: 2732-6.
63. Walsh CA, Birch MA, Fraser WD, Lawton R, Dorgan J, Walsh S, et al. Expression and secretion of parathyroid hormone-related protein by human bone-derived cells in vitro: effects of glucocorticoids. J Bone Miner Res 1995; 10: 17-25.
64. Horwitz MJ, Tedesco MB, Sereika SM, Hollis, BW, García-Ocaña A, Stewart AF. Direct Comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) (HPTHRP-(1-36)) versus HPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003; 88: 1063-9.
65. Horwitz MJ, Tedesco MB, Gundberg C, García-Ocaña A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 569-75.
66. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-76.
67. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Díez-Perez A, et al. The effect of teriparatida (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
68. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatida effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis Int 2005; 16: 510-6.
69. Lindsay R, Scheele W, Neer N, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction alter withdrawal of teriparatida in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
70. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14: 77-81.
71. Hurley M, Yao W, Lane NE. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int 2005; 16: 2080-4.
72. Lane NE, Sánchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998 ; 102: 1627-33.
73. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000; 11: 434-42.
74. Armen H Tashjian Jr AH, Gagel RF. Teriparatida (human PTH(1-34)): 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006; 21: 354-65.
75. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-21.
76. Wilker CE, Jolette J, Smith SY, Doyle N, Hardisty JF, Metcalf AJ, et al. A no observable carcinogenic effect dose-level identified in Fisher 344 rats following daily treatment with PTH (1-84) for 2 years: Role of the C-terminal PTH receptor. J Bone Miner Res 2004; 19: S1; S98.
77. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-21.
78. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatida (rhPTH(1-34)) are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32: 426-38.
79. Tashjian AH, Gagel RF. Teriparatida (Human PTH(1-34)): 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006; 21: 354-65.
80. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on riskof fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
81. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture riskin postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45
82. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999; 282: 1344-52.
83. Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
84. Chesnut CH, Silverman S, Andriano K, Genant HK, Gimona A, Harris S, et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109: 267-76.
85. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the riskof vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
86. McClung MR, Geusens P, Miller PD, Zippel H, Benson WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
87. Reginster JY, Seeman E, DeVernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peritoneal osteoporosis. TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-XXX.
88. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
89. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1-12.
90. Ilter E, Karalok H, Tufekci EC, Batur O. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 2006; 9: 129-34.
91. Millar PD, McClung MR, Macovei L, Stakkestad JA,, Luckey M, Bonvoisin B., et al. Monthly oral ibandronate therapy on postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005; 20: 1315-22.
92. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-17.
93. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
94. Deal C. The Use of Intermittent Human Parathyroid Hormone As a Treatment for Osteoporosis. Current Rheumatology Reports 2004, 6: 49-58.
95. Cosman F. Anabolic Therapy for Osteoporosis: Parathyroid Hormone. Current Osteoporosis Reports 2005, 3: 143-9.
96. Girotra M,Rubin MR, Bilezikian JP. Anabolic Skeletal Therapy for Osteoporosis. Arq Bras Endocrinol Metab 2006; 50: 745-54.
97. Quesada JM. Agentes anabólicos óseos para el tratamiento de osteoporosis. Endocrinol Nutr 2004; 51: 512-23.
98. Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 2007; 18: 45-7.
99. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-5.
100. Sackett DL, Rosenberg WMC, Gary JAM, Haynes RB, Richardson WS. Evidence based medicine: what is it and what it isn't. BMJ 1996; 312: 71-2.
101. Guerra Romero L. La medicina basada en la evidencia: un intento de acercar la ciencia al arte de la práctica clínica. Med Clin (Barc) 1996; 107: 377-82.
102. Jovell AJ, Navarro-Rubio MD. Evaluación de la evidencia científica. Med Clin (Barc) 1995; 105: 740-3.
103. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users' Guides to the Medical Literature: IX. A method for grading health care recommendations. JAMA 1995; 274: 1800-4.
104. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, et al. Combination teriparatida and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005; 20: 1905-11.
105. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatida? J Bone Miner Res. 2007; 22: 334.
106. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, et al. Reduced risk of back pain following teriparatida treatment: a meta-analysis. Osteoporos Int. 2006; 17: 273-80.
107. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, et al. One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. N Engl J Med 2005; 353: 555-65.